Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 80

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 80
---
       |

| • | beyond contractual warranties, the licensors of intellectual property to us or our affiliates own the                                  
 relevant patents and that those patents have not and will not be the subject of, or subject to, infringement, invalidity or revocation 
 actions.                                                                                                                               |

The steps we have taken to
protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our
intellectual property rights, both inside and outside of the United Kingdom and United States. The rights already granted under any of
our currently issued patents and those that may be granted under future issued patents may not provide us with the proprietary protection
or competitive advantages we are seeking. If we are unable to obtain and maintain patent protection for our technology and products, or
if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize technology and products
similar or superior to ours, and our ability to successfully commercialize our technology and products may be adversely affected.

With respect to patent rights,
we do not know whether any of the pending patent applications for any of our licensed compounds will result in the issuance of patents
that protect our technology or products, or which will effectively prevent others from commercializing competitive technologies and products.
Although we have a number of issued patents covering our technology, our pending applications cannot be enforced against third parties
practicing the technology claimed in such applications unless and until a patent issues from such applications. Further, the examination
process may require us to narrow the claims, which may limit the scope of patent protection that may be obtained. Because the issuance
of a patent is not conclusive as to its inventorship, scope, validity or enforceability, issued patents that we own or have licensed from
third parties may be challenged in the courts or patent offices in the European Union, United Kingdom, the United States and other foreign
jurisdictions. Overall, such challenges may result in the loss of patent protection, the narrowing of claims in such patents, or the invalidity
or unenforceability of such patents, which could limit our ability to stop others from using or commercializing similar or identical technology
and products, or limit the duration of the patent protection for our technology and products. Protecting against the unauthorized use
of our patented technology, trademarks and other intellectual property rights is expensive, difficult and may in some cases not be possible.
In some cases, it may be difficult or impossible to detect third party infringement or misappropriation of our intellectual property rights